Investors tend to move away from somewhat speculative stocks when the economic going gets rough. That partly explains why shares of Editas Medicine (NASDAQ: EDIT) have underperformed the broader market lately. After all, the gene-editing specialist currently has no approved products, generates little revenue, and is consistently unprofitable.

Still, relatively small clinical-stage biotechs can sometimes deliver excellent returns provided they deliver solid clinical and regulatory progress. Can Editas Medicine pull that off?

Editas Medicine's most advanced candidate is EDIT-301, which targets sickle cell disease and beta-thalassemia. These rare blood-related disorders are attractive targets as they have been hard to treat and causes extreme hardships to patients. For instance, people with beta-thalassemia typically require regular blood transfusions.

Continue reading

Source Fool.com